Comparison of the effectiveness, safety, and costs of anti‐Parkinson drugs: A multiple‐center retrospective study
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14531 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Wenting Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
This study aimed to systematically compare the effectiveness, safety, and costs of different anti‐Parkinson drugs (APDs).
Methods
This is a multi‐center study that retrospectively analyzed the data of 8420 outpatients with PD from 2014 to 2019 across 30 tertiary hospitals in China. The effectiveness was evaluated by changes in total dosages of APDs, normalized by levodopa equivalent dose (LED) and presented as ΔLEDs; levodopa equivalent dose cost (LEDc) represented the daily cost of APDs; and newly added diagnostics were represented as APDs‐related adverse events.
Results
A total of 384 patients with eligible medical records for three consecutive years were enrolled. Patients treated with carbidopa/levodopa or levodopa/benserazide had significantly lower mean ΔLEDs than other groups ( p < 0.01), followed by pramipexole and selegiline. The piribedil group had the highest ΔLEDs, with mean differences of 112.56–355.04 mg compared to other groups ( p < 0.01). Meanwhile, LEDc in the levodopa/benserazide, carbidopa/levodopa, and piribedil groups were significantly lower than those in pramipexole or selegiline groups ($0.088–0.135/day for levodopa/benserazide; $0.070–0.126/day for carbidopa/levodopa; $0.112–0.138/day for piribedil; $0.290–0.332/day for pramipexole; $0.229–0.544/day for selegiline; p < 0.01). Patients with piribedil had more adverse events, with an incidence rate of 35.7%, followed by levodopa/benserazide (25.6%), selegiline (23.5%), carbidopa/levodopa (23.3%), and pramipexole (16.4%). Pramipexole showed a lower incidence rate of adverse events than piribedil, including neuropsychiatric symptoms ( p = 0.006), headache/dizziness ( p = 0.016), and gastrointestinal symptoms ( p = 0.031).
Conclusions
Carbidopa/levodopa or levodopa/benserazide might exhibit better clinical improvement with less medical cost, while piribedil presented less clinical improvement but a higher risk of headache/dizziness, gastrointestinal, and neuropsychiatric symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Peking University Third Hospital, Beijing, China.
- Department of Pharmacy, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Wenting Li, Zhanmiao Yi
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, W., Zhang, H., Zhang, Y., Wang, K., Hui, J., & Yi, Z. (2024). Comparison of the effectiveness, safety, and costs of anti‐Parkinson drugs: A multiple‐center retrospective study. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14531
Vancouver
Li W, Zhang H, Zhang Y, Wang K, Hui J, Yi Z. Comparison of the effectiveness, safety, and costs of anti‐Parkinson drugs: A multiple‐center retrospective study. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14531
BibTeX
@article{Li2024,
author = {Li, Wenting and Zhang, Hua and Zhang, Yuan and Wang, Ke and Hui, Jiaojiao and Yi, Zhanmiao},
title = {Comparison of the effectiveness, safety, and costs of anti‐Parkinson drugs: A multiple‐center retrospective study},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14531}
}
EUVIMED